• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • GB9706.1-2020 implementation explained by NMPA

GB9706.1-2020 implementation explained by NMPA

GB9706.1-2020 implementation explained
Friday, 28 April 2023 / Published in Medical Device, News, NMPA Registration in China

GB9706.1-2020 implementation explained by NMPA

GB9706.1-2020 implementation has been explained further by the National Medical Products Administration (NMPA) in a recent Interpretation of the Circular on the Implementation of GB 9706.1-2020 (No.14-2023) which was announced on March 16, 2023.

The latest clarification addresses several questions on how to implement the new standards, supporting standards and concurrent standards for medical electrical equipment in China.

How to continue the registration if already registered before the implementation date of GB9706.1-2020 and its supporting standards?

For those who apply for renewal registration before the implementation date of the new GB9706 series standards specified in Notice No.14-2023, they can be evaluated for approval according to the requirements of the original standards. For those who apply for renewal registration after the implementation date of the new GB9706 series standards specified in Notice No.14-2023, they should be evaluated and approved according to the requirements of the new GB9706 series standards.

How to implement the new version of GB9706 series standards in product registration and filing work for specialized standards that are recommended standards?

The recommended standard GB/T9706.266 “Medical electrical equipment – Part 2-66: Particular requirements for the basic safety and essential performance of hearing instruments and hearing instrument systems” has not yet been published. In order to encourage the implementation of the recommended standard, for the product registration work applicable to GB/T9706.266, GB9706.1-2020 and its supporting parallel standards can be chosen by the enterprise:

  • If an enterprise chooses to implement GB/T9706.266, GB9706.1-2020 and its supporting parallel standards can be implemented together with GB/T9706.266 after its release.
  • If the enterprise chooses not to implement GB/T9706.266, GB9706.1-2020 and its supporting parallel standards should be implemented from May 1, 2023.

For products with implementation dates of specialized standards after December 31, 2025, how will product registration and filing be carried out according to the new GB9706 series standards?

For proprietary standards with implementation dates after December 31, 2025, products that are first registered or filed for recordation after the implementation date of the relevant standards specified in Notice No.14-2023 shall submit inspection reports that comply with the requirements of the new version of the GB9706 series standards. For products that were registered and accepted before this date, inspections, evaluations, and approvals may be conducted in accordance with the original standards.

How to change the product manual and label for registered products?

After the product completes the registration or filing of changes in the new GB9706 series standards, it can modify the instructions and labels based on the change documents.

Further Information

Read our article on GB9706.1-2020 and its supporting standards.

Discover our services for medical device registration, renewals and NMPA Legal Agent.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

New Guidelines in support of the Implementation of the CSAR: New Online Account, Raw Material Information, Efficacy Tests, and Annual Reports
China medical device classification
China medical device classification results released for July to September 2022
Regulatory Updates for Intravascular Catheters in September 2021

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP